Perimeter Medical Imaging AI: Upcoming Financial Results Call
Perimeter Medical Imaging AI Announces Financial Results Conference Call
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) is gearing up to share its financial performance for the fourth quarter and full year 2024. This pivotal event is expected to take place after market closure on March 26. The management team at Perimeter will also coordinate a conference call to discuss the financial results, offering insight into the company's achievements and future goals.
Details of the Conference Call
The financial results call is scheduled for Wednesday, March 26 at 5:00 pm Eastern Time. Investors interested in participating can connect via two dial-in numbers: 1-800-717-1738 for individuals in Canada and the United States or 1-646-307-1865 for international callers.
Live Broadcast Availability
For those unable to join the call live, Perimeter will stream the event on its official website under the "News/Events" section within the Investors area. This feature offers listeners an opportunity to catch up on key announcements concerning the company.
Company Overview
Perimeter Medical Imaging AI is at the forefront of innovation within the medical technology sector, concentrated on enhancing cancer surgery outcomes. With headquarters situated in Toronto and Dallas, the company utilizes state-of-the-art imaging tools designed to meet significant medical needs. One of its flagship products, the Perimeter S-Series OCT system, is FDA-cleared and provides real-time, detailed visualization of excised tissues at the cellular level.
The company is also advancing its Perimeter B-Series OCT, integrated with ImgAssist AI technology, which is currently undergoing pivotal clinical trials. This development is supported by financial assistance of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas. The ticker symbol PINK eloquently reflects the iconic pink ribbons that symbolize Breast Cancer Awareness Month, showcasing the company’s commitment to addressing breast cancer concerns.
Regulatory Status of Perimeter Devices
It is essential to note that the Perimeter B-Series OCT is classified as investigational and not available for purchase within the United States. Conversely, the Perimeter S-Series OCT possesses general indications under its 510(k) clearance, although its specific application for breast tissue doesn't have direct FDA evaluation yet. The company actively emphasizes that while the technology is promising, detailed safety and efficacy studies are ongoing to solidify its clinical utility.
Investing in the Future
As the healthcare landscape continues to evolve, Perimeter Medical Imaging AI remains committed to expanding its presence and technological capabilities in the medical sector. The upcoming financial results call is a significant opportunity for investors and stakeholders to glean insights into the company's progress and direction. The healthcare industry is competitive; thus, it’s crucial for stakeholders to remain informed of Perimeter's strategy and performance metrics.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to announce Perimeter's financial results for the fourth quarter and full year 2024, along with providing strategic updates.
How can investors participate in the call?
Investors can dial in using specific phone numbers provided by the company, with options for both North American and international participants.
Is the call available for replay?
Yes, the call will be available for live streaming on the company's official website, allowing for replay opportunities.
What technologies does Perimeter develop?
Perimeter specializes in advanced imaging tools for cancer surgery, specifically the Perimeter S-Series and the investigational B-Series OCT systems integrated with AI technology.
How does Perimeter contribute to cancer awareness?
The company's ticker symbol PINK highlights its connection to Breast Cancer Awareness Month, focusing its efforts on supporting technologies that address breast cancer surgery needs.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
